Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study Guardant Health, Inc. a leading
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer Johnson &
Research presented at the Society for Behavioral Medicine’s Annual Meeting furthers Omada’s robust body of evidence, highlighting the potential of personalized care paths to improve
Immunovia , the pancreatic cancer diagnostics company, announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as
On Monday, Microsoft Corp. is unveiling Microsoft Dragon Copilot, the first AI assistant for clinical workflow that brings together the trusted natural language voice dictation capabilities
Fuel up with free Health Tech Insights
